

Notice Regarding Investment in PeptiStar Inc.

Toagosei Co., Ltd. announced today that it has made a 500-million-yen equity investment in PeptiStar Inc., a peptide and nucleic acid contract development and manufacturing organization (CDMO), by underwriting a third-party allocation of shares in the company.

Established in 2017, PeptiStar Inc. is a peptide and nucleic acid drug substance CDMO. The company aims to support the early development of new drugs. It works to achieve this aim by strategically consolidating various cutting-edge technologies scattered throughout Japan to improve the efficiency of the supply chain that acts as a bottleneck in the research and development process.

Toagosei aims to commercialize products in the pharmaceutical field. The company works to achieve this aim by using NUCLEOLARON cellular membrane permeable peptides developed by the Institute for Advanced Sciences as a drug delivery system to contribute to innovation in new drug development technology. NUCLEOLARON enables the delivery of drugs to the inside of organs and cells difficult to reach with drugs in conventional drug delivery systems. It also reduces the quantity of drugs used, so it is expected to improve quality of life.

Toagosei will participate in an all-Japan structure in the nucleic acid/peptide pharmaceutical industry by investing in PeptiStar Inc. In doing so, it will advance its development plans for NUCLEOLARON and promote the early commercialization of medical care products.

Profile of PeptiStar Inc.

Name	PeptiStar Inc.
Head office address	2-5-1 Mishima, Settsu, Osaka
Established	September 1, 2017
President & CEO	Shinichiro Fujjie
Business lines	Research, development, manufacturing, trading and experimental manufacturing of pharmaceuticals and their intermediates

< Contact information > CORPORATE COMMUNICATION DEPARTMENT
e-mail address : irpr@toagosei.co.jp